Mechanisms of tumor cell invasion and angiogenesis in the central nervous system

Frontiers in Bioscience

Volumn 8, Issue , 2003, Pages

  Visted, Therese ^a   Enger, Per Oyvind ^a   Lund Johansen, Morten ^a   Bjerkvig, Rolf ^a  

^a UNIVERSITY OF BERGEN   (Norway)

Author keywords

Angiogenesis; Antiangiogenic therapy; Cell Based Therapy; Genomics; Gliomas; Invasion; Malignant Transfomation; Neural Precursor Cells; Neural Stem Cells; Proteomics; Review; SAGE

Indexed keywords

4 DEDIMETHYLAMINOSANCYCLINE; AE 941; ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; ANGIOSTATIN; ANGIOZYME; ANTISENSE OLIGODEOXYNUCLEOTIDE; ATRASENTAN; CELECOXIB; CGS 27023A; CHELATING AGENT; CILENGITIDE; CM 101; COMBRETASTATIN; COPPER; CYTOTOXIC AGENT; D 2163; ENDOSTATIN; FUMAGILLOL CHLOROACETYLCARBAMATE; GAMMA INTERFERON; IM 862; INTERLEUKIN 4; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; MONOCLONAL ANTIBODY LM 609; PNU 145156 E; PRINOMASTAT; RIBOZYME; SEMAXANIB; SQUALAMINE; SU 66668; SURAMIN; TANOMASTAT; THALIDOMIDE; UNINDEXED DRUG; VASCULOTROPIN ANTIBODY; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 2; VATALANIB; ZDO 101; ZK 22584;

ANGIOGENESIS; ASTROCYTE; ASTROCYTOMA; CANCER INHIBITION; CANCER INVASION; CELL BASED GENE THERAPY; CELL FUNCTION; CELL INVASION; CELL MOTION; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL TRIAL; DEVELOPMENTAL BIOLOGY; DISEASE COURSE; DRUG DELIVERY SYSTEM; GLIOMA; GLIOMA CELL; HUMAN; NONHUMAN; PATHOLOGICAL ANATOMY; PHENOTYPE; PRECURSOR; REVIEW; STEM CELL; TERATOGENICITY; TUMOR CELL; TUMOR VASCULARIZATION; VIRAL GENE THERAPY;

EID: 3142658178     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: None     Document Type: Review

References (159)

1. Zadeh G & A Guha: Expression and Functional Role of Angiopoietins and their Cognate Receptors. Front Biosci 8, e128-137, (2003)
2. Brat DJ, K Balveen & EG VanMeir: Genetic modulation of hypoxia induced gene expression and angiogenesis: relevance to brain tumors. Front Biosci 8, d100-116, (2003)
3. Nakada M, Y Okada, J Yamashita: The Role of Matrix Metalloproteinases in Glioma Invasion. Front Biosci 8, e261-269, (2003)
4. Price J, BP Williams & E Grove: Cell lineage in the cerebral cortex. Development (Suppl 2), 23-28 (1991)
5. Williams BP, J Read & J Price: The generation of neurons and oligodendrocytes from a common precursor cell. Neuron 7, 685-693 (1991)
6. Walsh C & CL Cepko: Widespread dispersion of neuronal clones across functional regions of the cerebral cortex. Science 255, 434-440 (1992)
7. Walsh C & CL Cepko: Clonally related cortical cells show several migration patterns. Science 241, 1342-1345 (1988)
8. Turner DL & CL Cepko: A common progenitor for neurons and glia persists in rat retina late in development. Nature 328, 131-136 (1987)
9. Cameron HA, CS Woolley, BS McEwen, & E Gould: Differentiation of newly born neurons and glia in the dentate gyrus of the adult rat. Neuroscience 56, 337-344 (1993)
10. Gage FH, G Kempermann, TD Palmer, DA Peterson & J Ray: Multipotent progenitor cells in the adult dentate gyrus. J Neurobiol 36, 249-266 (1998)
11. Kaplan MS & DH Bell: Mitotic neuroblasts in the 9-day-old and 11-month-old rodent hippocampus. J Neuroscience 4, 1429-41(1984)
12. Garcia JM, F Doetsch, H Wichterle, DA Lim & A Alvarez-Buylla: Architecture and cell types of the adult subventricular zone: in search of the stem cells. J Neurobiol 36, 234-48 (1998)
13. Alvarez-Buylla A, JM Garcia-Verdugo & AD Tramontin: A unified hypothesis on the lineage of neural stem cells. Nat Rev Neuroscience 2, 287-293 (2001)
14. Rao MS & M Mayer-Proschel: Glial-restricted precursors are derived from multipotent neuroepithelial stem cells. Dev Biol 188, 48-63 (1997)
15. Pagano SF, R Galli, M Girelli, L Cova, EA Parati, M Mora & AL Vescovi: Epigenetic regulation of differentiation in human neural stem cells. Soc Neurosci 25, 914-915 (1999)
16. Price J & L Thurlow: Cell lineage in the rat cerebral cortex: A study using retroviralmediated gene transfer. Development 104, 473-482 (1988)
17. Reynolds BA, W Tetzlaff & S Weiss: A multipotent EGF-responsive striatal embryonic progenitor cell produces neurons and astrocytes. J Neurosci 12, 4563-4574 (1992)
18. Reynolds BA & S Weiss: Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science 255, 1707-1710 (1992)
19. Svendsen CN, KR Prowse, MHK Linskens & E Jauniaux: Precursor cells isolated from the developing human CNS show regional specificity and lack telomerase expression. Soc Neurosci 25, 102-105 (1999) [Abstract]
20. Temple S: Division and differentiation of isolated CNS blast cells in microculture. Nature 340, 471-473 (1989)
21. Uchida N, D He, MJ Reitsma, M Masek, L Weissman, FH Gage & D Buck: Direct isolation of human neural stem cells from fetal brain by cell sorting. Soc Neurosci 25, 701-703 (1999) [Abstract]
22. Noble M, N Gutowski, K Bevan, U Engel, M Linskey, J Urenjak, K Bhakoo & S Williams: From rodent glial precursor cell to human glial neoplasia in the oligodendrocyte-type-2 astrocyte lineage. Glia 15, 222-30 (1995)
23. Noble M & M Mayer-Proschel: Growth factors, glia and gliomas. J Neurooncol 35, 193-209 (1997)
24. Holland EC: Progenitor cells and glioma formation. Curr Opin Neurol 14, 683-8.
25. Palmer T, DEA Markakis, AR Willhoite, F Safar, & FH Gage: Fibroblast growth factor-2 activates a latent neurogenic program in neural stem cells from diverse regions of the adult CNS. J Neurosci 19, 8487-8497 (1999)
26. Morshead CM, BA Reynolds, CG Craig, MW McBurney, WA Staines, D Morassutti, S Weiss & D van der Kooy: Neural stem cells in the adult mammalian forebrain: A relatively quiescent subpopulation of subependymal cells. Neuron 13, 1071-1082 (1994)
27. Gage FH, J Ray & LJ Fisher: Isolation, characterization & use of stem cells from the CNS. Annu Rev Neurosci 18, 159-192 (1995)
28. Morrison SJ, NM Shah & DJ Anderson: Regulatory mechanisms in stem cell biology. Cell 88, 287-298 (1997)
29. Gage FH: Discussion point: stem cells of the central nervous system. Curr Opin Neurobiol 8, 671-675 (1998)
30. Alvarez-Buylla A & S Temple: Stem cells in the developing and adult nervous system. J Neurobiol 36, 105-110 (1998)
31. Doetsch F, I Caille, DA Lim, JM Garcia-Verdugo & A Alvarez-Buylla: Subventricular zone astrocytes are neural stem cells in the adult mammalian brain. Cell 97, 1-20 (1999)
32. Dahlstrand J, VP Collins & U Lendahl: Expression of the class VI intermediate filament nestin in human central nervous system tumors. Cancer Res 52, 5334-41 (1992)
33. Sallinen SL, PK Sallinen, HK Haapasalo, HJ Helin, PT Helen, P Schraml, OP Kallioniemi & J Kononen: Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques. Cancer Res 60, 6617-22 (2000)
34. Wikstrand CJ, P Fredman, L Svennerholm & DD Bigner: Detection of glioma-associated gangliosides GM2, GD2, GD3, 3′-isoLM1 3′,6′-isoLD1 in central nervous system tumors in vitro and in vivo using epitope-defined monoclonal antibodies. Prog Brain Res 101, 213-23 (1994)
35. von Holst H, C Nygren, K Bostrom, VP Collins & P Fredman: The presence of foetal ganglioside antigens 3′-isoLM1 and 3′6-isoLD1 in both glioma tissue and surrounding areas from human brain. Acta Neurochir (Wien) 139, 141-145 (1997)
36. Fredman P, H Holst, VP Collins, B Dellheden & L Svennerholm: Expression of gangliosides GD3 and 3′-isoLM1 in autopsy brains from patients with malignant tumors. J Neurochem 60, 99-105 (1993)
37. Sung CC, DK Pearl, SW Coons, BW Scheithauer, PC Johnson & AJ Yates: Gangliosides as diagnostic markers of human astrocytomas and primitive neuroectodermal tumors. Cancer 74 3010-3022 (1994)
38. Oohira A, F Matsui, Y Tokita, S Yamauchi & S Aono: Molecular interactions of neural chondroitin sulfate proteoglycans in the brain development. Arch Biochem Biophys 374, 24-34(2000)
39. Diers-Fenger M, F Kirchhoff, H Kettenmann, JM Levine & J Trotter: AN2/NG2 protein-expressing glial progenitor cells in the murine CNS: isolation, differentiation, and association with radial glia. Glia 34, 213-28 (2001)
40. Shoshan Y, A Nishiyama, A Chang, S Mork, GH Barnett, JK Cowell, BD Trapp & SM Staugaitis: Expression of oligodendrocyte progenitor cell antigens by gliomas: implications for the histogenesis of brain tumors. Proc Natl Acad Sci U S A. 96, 10361-10366 (1999)
41. Stallcup WB & L Beasley: Bipotential glial precursor cells of the optic nerve express the NG2 proteoglycan. J Neurosci 7, 2737-2744 (1987)
42. Nishiyama A, KJ Dahlin, JT Prince, SR Johnstone & WB Stallcup: The primary structure of NG2, a novel membrane-spanning proteoglycan. J Cell Biol 144, 359-371 (1991)
43. Chekenya M, M Hjelstuen, PO Enger, F Thorsen, AL Jacob, B Probst, O Haraldseth, G Pilkington, A Butt, JM Levine & R Bjerkvig: NG2 proteoglycan promotes angiogenesis-dependent tumor growth in CNS by sequestering angiostatin. FASEB J 16, 586-588 (2002)
44. Rubinstein LJ, MM Herman & SR VanderBerg: Differentiation and anaplasia in central neuroepithelial tumors. Prog Exp Tumor Res 27, 32-48 (1984)
45. Law AK, V Pencea , CR Buck & MB Luskin: Neurogenesis and neuronal migration in the neonatal rat forebrain anterior subventricular zone do not require GFAP-positive astrocytes. Dev Biol 216, 622-634 (1999)
46. Bloom WH, KC Carstairs & MR Crompton: Autologous glioma transplantation. Lancet 1, 77-78 (1960)
47. th Edition, Vol. 1, Arnold, London, Sydney Aucland 117-140 (1998)
48. Pedersen PH, G Rucklidge, SJ Mork, AJA Terzis, O Engebraaten, M Lund-Johansen, EO Backlund, OD Laerum & R Bjerkvig: Leptomeningeal tissue: A barrier against brain tumor cell invasion. J Natl Cancer Inst 86, 1593-1599 (1994)
49. Pilkington GJ: The paradox of neoplastic glial cell invasion of the brain and apparent metastatic failure. Anticancer Res 17, 4103-4105(1997)
50. Marienhagen K, PH Pedersen, AJA Terzis, OD Laerum, H Arnold & R Bjerkvig: Interactions between fetal rat brain cells and mature brain tissue in vivo and vitro. Neuropath and Appl Neurobiol 20, 130-143 (1994)
51. Hynes RO: Integrins: versality, modulation, and signalling in cell adhesion. Cell 69, 11-25 (1992)
52. Ruoslahti E: Control of cell motility and tumor invasion by extracellular matrix interactions. Br J Cancer 66, 239-242 (1992)
53. Rao JS, A Rayford, RA Morantz, BW Festoff & R Sawaya: Increased levels of plasminogen activator inhibitor-1 (PAI-1) in human brain tumors. J Neurooncol 17, 215-221 (1993)
54. Chintala SK, JC Tonn & JS Rao: Matrix metalloproteinases and their biological function in human gliomas. Int J Dev Neurosci 17, 495-502 (1999)
55. Eisenberg D, EM Marchotte, I Xenarios & TO Yeates: Protein function in the post-genomic era. Nature 405: 823-826, (2000)
56. Uetz P, L Giot, G Cagney, TA Mansfield, RS Judson, JR Knight, D Lockshon, V Narayan, M Srinivasan, P Pochart, A Qureshi-Emili, Y Li, B Godwin, D Conover, T Kalbfleisch, G Vijayadamodar, M Yang, M Johnston, S Fields & JM Rothberg: A comprehensive analysis of protein-protein interactions in Saccharomyces cerevisiae. Nature 403, 623-627 (2000)
57. Mahesparan R, BB Tysnes, TA Read, PO Enger, R Bjerkvig & M Lund-Johansen: Extracellular matrix-induced cell migration from glioblastoma biopsy specimens in vitro. Acta Neuropathol (Berl) 97:231-239 (1999)
58. Engerman RL, D Pfaffenbach & MD Davis: Cell turnover of capillaries. Lab Invest 17, 738-743 (1967)
59. Hobson B & J Denekamp: Endothelial proliferation in tumours and normal tissues: continuous labelling studies. Br J Cancer 49, 405-413 (1984)
60. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1, 27-31 (1995)
61. Folkman J: Angiogenesis. In: Braunwald, E, Fauci, AS, Kasper, DL, Hauser, SL, Longo, DL & Jameson, JL (eds.) Harrison's textbook of internal medicine, 517-530, McGrawen-Hill (2001)
62. Hanahan D & J Folkman: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86, 353-364 (1996)
63. Pedersen PH, GO Ness, O Engebraaten O, R Bjerkvig, JR Lillehaug & OD Laerum: Heterogeneous response to the growth factors [EGF, PDGF (bb), TGF-alpha, bFGF, IL-2] on glioma spheroid growth, migration and invasion. Int J Cancer 56, 255-61 (1994)
64. Auguste P, DB Gursel, S Lemiere, D Reimers, P Cuevas, F Carceller, JP Di Santo & A Bikfalvi: Inhibition of fibroblast growth factor/fibroblast growth factor receptor activity in glioma cells impedes tumor growth by both angiogenesis-dependent and-independent mechanisms. Cancer Res 61 1717-26 (2001)
65. Thomas KA: Vascular endothelial growth factor, a potent and selective angiogenic agent. J Biol Chem 271, 603-606 (1996)
66. Shibuya M: Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct Funct 26, 25-35 (2001)
67. Senger DR, SJ Galli, AM Dvorak, CA Perruzzi, VS Harvey & HF Dvorok: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219, 983-985 (1983)
68. Rak J, Y Mitsuhashi, L Bayko, J Filmus, S Shirasawa, T Sasazuki & RS Kerbel: Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 55, 4575-4580 (1995)
69. Shweiki D, A Itin, D Soffer & E Keshet: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359, 843-845 (1992)
70. Eberhard A, S Kahlert, V Goede, B Hemmerlein, KH Plate & HG Augustin: Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 60, 1388-1393 (2000)
71. Goldman CK, J Kim, WL Wong, V King, T Brock & GY Gillespie: Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol Biol Cell 4, 121-133 (1993)
72. Tooth H: Some observations on the growth and survival period of intracranial tumours, based on the records of 500 cases, with special reference to the pathology of the gliomata. Brain 35, 61-108 (1912)
73. Machein MR, J Kullmer, V Ronicke, U Machein, M Krieg, A Darnert, G Breier, W Risau & KH Plate: Diffrential downregulation of VEGF by dexamethasone in normoxic and hypoxic rat glioma cells. Neuropath Appl Neurobiol 25, 104-112 (1999)
74. Plate KH, G Breier, HA Weich, HD Mennel & W Risau: Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int J Cancer 59, 520-529 (1994)
75. Giese A, & M Westphal: Glioma invasion in the central nervous system. Neurosurgery 39, 235-250; discussion 250-232 (1996)
76. Engebraaten O, R Bjerkvig, PH Pedersen & OD Laerum: Effects of EGF, bFGF, NGF and PDGF(bb) on cell proliferative, migratory and invasive capacities of human brain-tumour biopsies in vitro. Int J Cancer 53, 209-214 (1993)
77. Vajkoczy P, R Goldbrunner, M Farhadi, G Vince, L Schilling, JC Tonn, P Schmiedek & MD Menger: Glioma cell migration is associated with glioma-induced angiogenesis in vivo. Int J Dev Neurosci 17, 557-563 (1999)
78. Vajkoczy P, MD Menger, R Goldbrunner, S Ge, TA Fong, B Vollmar, L Schilling, A Ullrich, KP Hirth, JC Tonn, P Schmiedek & SA Rempel: Targeting angiogenesis inhibits tumor infiltration and expression of the proinvasive protein SPARC. Int J Cancer 87, 261-268 (2000)
79. O'Reilly MS, L Holmgren, Y Shing, C Chen, RA Rosenthal, M Moses, WS Lane, Y Cao, EH Sage & J Folkman: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79, 315-328 (1994)
80. O'Reilly MS, T Boehm, Y Shing, N Fukai, G Vasios, WS Lane, E Flynn, JR Birkhead, BR Olsen & J Folkman: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88, 277-285 (1997)
81. Cao Y, A Chen, SS An, RW Ji, D Davidson & M Llinas: Kringle 5 of plasminogenis a novel inhibitor of endothelial cell growth. J Biol Chem 272, 22924-22928 (1997)
82. Cao R, HL Wu, N Veitonmaki, P Linden, J Farnebo, GY Shi & Y Cao: Suppression of angiogenesis and tumor growth by the inhibitor K1-5 generated by plasmin-mediated proteolysis. Proc Natl Acad Sci U S A 96, 5728-5733 (1999)
83. Pike SE, L Yao, KD Jones, B Cherney, E Appella, K Sakaguchi, H Nakhasi, J Teruya-Feldstein, P Wirth, G Gupta & G Tosato: Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth. J Exp Med 188, 2349-2356 (1998)
84. O'Reilly MS, S Pirie-Shepherd, WS Lane & J Folkman: Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 285, 1926-1928 (1999)
85. Muller G, J Behrens, U Nussbaumer, P Bohlen & W Birchmeier: Inhibitory action of transforming growth factor beta on endothelial cells. Proc Natl Acad Sci U S A 84, 5600-5604 (1987)
86. Maione TE, GS Gray, J Petro, AJ Hunt, AL Donner, SI Bauer, HF Carson & RJ Sharpe: Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 247, 77-79 (1990)
87. Voest EE, BM Kenyon, MS O'Reilly, G Truitt, RJ D'Amato & J Folkman: Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 87, 581-586 (1995)
88. Ribatti D, A Vacca, M Iurlaro, R Ria, L Roncali & F Dammacco: Human recombinant interferon alpha-2a inhibits angiogenesis of chick area vasculosa in shell-less culture. Int J Microcirc Clin Exp 16, 165-169 (1996)
89. Cao Y, C Chen, JA Weatherbee, M Tsang & J Folkman: Gro-beta, a -C-X-C- chemokine, is an angiogenesis inhibitor that suppresses the growth of Lewis lung carcinoma in mice. J Exp Med 182, 2069-2077 (1995)
90. Angiolillo AL, C Sgadari, DD Taub, F Liao, JM Farber, S Maheshwari, HK Kleinman, GH Reaman & G Tosato: Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med 182, 155-162 (1995)
91. Kendall RL & KA Thomas: Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci U S A 90, 10705-10709 (1993)
92. Hanneken A, W Ying, N Ling & A Baird: Identification of soluble forms of the fibroblast growth factor receptor in blood. Proc Natl Acad Sci U S A 91, 9170-9174 (1994)
93. Maisonpierre PC, C Suri, PF Jones, S Bartunkova, SJ Wigand, C Radziejewski, D Compton, J McClain, TH Aldrich, N Papadopoulos, TJ Daly, S Davis, TN Sato & GD Yancopoulos: Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 211, 55-60 (1997)
94. Good DJ, PJ Polverini, F Rastinejad, MM Le Beau, RS Lemons, WA Frazier & NP Bouck: A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci U S A 87, 6624-6628 (1990)
95. Vazquez F, G Hastings, MA Ortega, TF Lane, S Oikemus, M Lombardo & ML Iruela-Arispe: METH-1, a human ortholog of ADAMTS-1, and METH-2 are members of a new family of proteins with angio-inhibitory activity. J Biol Chem 274, 23349-23357 (1999)
96. Takigawa M, Y Nishida, F Suzuki, J Kishi, K Yamashita & T Hayakawa: Induction of angiogenesis in chick yolk-sac membrane by polyamines and its inhibition by tissue inhibitors of metalloproteinases (TIMP and TIMP-2). Biochem Biophys Res Commun 171, 1264-1271 (1990)
97. Brooks PC, S Silletti, TL von Schalscha, M Friedlander & DA Cheresh: Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell 92, 391-400 (1998)
98. Zhang M, O Volpert, YH Shi & N Bouck: Maspin is an angiogenesis inhibitor. Nat Med 6, 196-199 (2000)
99. Kamphaus GD, PC Colorado, DJ Panka, H Hopfer, R Ramchandran, A Torre, I Maeshima, JW Mier, VP Sukhatme & R Kalluri: Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. J Biol Chem 275, 1209-1215 (2000)
100. Colerado PC, A Torre, G Kamphaus, Y Maeshima, H Hopfar, K Takahashi, R Volk, ED Zamborsky, S Herman, PK Sarkar, MB Ericksen, M Dhanabal, M Simons, M Post, DW Kufe, RR Weichselbaum, VP Sukhatme & R Kalluri: Anti-angiogenic cues from vascular basement membrane collagen. Cancer Res 60, 2520-2526 (2000)
101. Maeshima Y, PC Colerado & R Kalluri: Two RGD-independent alpha vbeta 3 integrin binding sites on tumstatin regulate distinct anti-tumor properties. J Biol Chem 275, 23745-23750 (2000)
102. Dawson DW, O Volpert, P Gillis, SE Crawford, H Xu, W Benedict & NP Bouck: Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 285, 245-248 (1999)
103. Moses MA, D Wiederschain, I Wu, CA Fernandez, V Ghazizadeh, WS Lane, E Flynn, A Sytkowski, T Tao & R Langer: Troponin I is present in human cartilage and inhibits angiogenesis. Proc Natl Acad Sci U S A 96, 2645-2650 (1999)
104. Clapp C, JA Martial, RC Guzman, F Rentier-Delure & RI Weiner: The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis. Endocrinology 133, 1292-1299 (1993)
105. Jackson D, OV Volpert, N Bouck & DI Linzer: Stimulation and inhibition of angiogenesis by placental proliferin and proliferin-related protein. Science 266, 1581-1584 (1994)
106. Ramchandran R, M Dhanabal, R Volk, MJ Waterman, M Segal, H Lu, B Knebelmann & VP Sukhatme: Antiangiogenic activity of restin, NC10 domain of human collagen XV: comparison to endostatin. Biochem Biophys Res Commun 255, 735-739 (1999)
107. Hsu SC, OV Volpert, PA Steck, T Mikkelsen, PJ Polverini, S Rao, P Chou & NP Bouck: Inhibition of angiogenesis in human glioblastomas by chromosome 10 induction of thrombospondin-1. Cancer Res 56, 5684-91 (1996)
108. Giri D & M Ittmann: Inactivation of the PTEN tumor suppressor gene is associated with increased angiogenesis in clinically localized prostate carcinoma. Hum Pathol 30, 419-24 (1999)
109. Tenan M, G Fulci, M Albertoni, AC Diserens, MF Hamou, M El Atifi-Borel, JJ Feige, MS Pepper & EG Van Meir: Thrombospondin-1 is downregulated by anoxia and suppresses tumorigenicity of human glioblastoma cells. J Exp Med 191, 1789-98 (2000)
110. Pijuan-Thompson V, JR Grammer, J Stewart, RL Silverstein, SF Pearce, GP Tuszynski, JE Murphy-Ullrich & CL Gladson: Retinoic acid alters the mechanism of attachment of malignant astrocytoma and neuroblastoma cells to thrombospondin-1. Exp Cell Res 249, 86-101 (1999)
111. Zagzag D, A Hooper, DR Friedlander, W Chan, J Holash, SJ Wiegand , GD Yancopoulos & M Grumet: In situ expression of angiopoietins in astrocytomas identifies angiopoietin-2 as an early marker of tumor angiogenesis. Exp Neurol 159, 391-400 (1999)
112. Gladson CL: Expression of integrin alpha v beta 3 in small blood vessels of glioblastoma tumors. J Neuropathol Exp Neurol 55, 1143-9 (1996)
113. Kunkel P, S Muller, P Schirmacher, D Stavrou, R Fillbrandt, M Westphal & Lamszus K: Expression and localization of scatter factor/hepatocyte growth factor in human astrocytomas. Neuro-oncol 3, 82-8 (2001)
114. Tanaka T, Y Cao, J Folkman & HA Fine: Viral vector-targeted antiangiogenic gene therapy utilizing an angiostatin complementary DNA. Cancer Res 58, 3362-3369 (1998)
115. Saleh M, A Wiegmans, Q Malone, SS Stylli & AH Kaye: Effect of in situ retroviral interleukin-4 transfer on established intracranial tumors. J Natl Cancer Inst 91, 438-445 (1999)
116. Machein MR, W Risau & KH Plate: Antiangiogenic gene therapy in a rat glioma model using a dominant-negative vascular endothelial growth factor receptor 2. Hum Gene Ther 10, 1117-28 (1999).
117. Saleh M, NK Jonas, A Wiegmans & SS Stylli: The treatment of established intracranial tumors by in situ retroviral IFN-gamma transfer. Gene Ther 7, 1715-24 (2000)
118. Yamanaka R, SA Zullo, J Ramsey, M Onodera, R Tanaka, M Blaese & KG Xanthopoulos: Induction of therapeutic antitumor antiangiogenesis by intratumoral injection of genetically engineered endostatin-producing Semliki Forest virus. J Natl Cancer Inst 91, 438-45 (1999)
119. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 285, 1182-1186 (1971)
120. Folkman J: Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 175, 409-16 (1972)
121. Harris AL: Antiangiogenesis for cancer therapy. Lancet 349 (Suppl 2), 1113-5 (1997)
122. Zetter BR: Angiogenesis and tumor metastasis. Annu Rev Med 49, 407-24 (1998)
123. Boehm T, J Folkman, T Browder & MS O'Reilly: Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390, 404-7 (1997)
124. Figg WD, W Dahut, P Duray, M Hamilton, A Tompkins, SM Steinberg, E Jones, A Premkumar, WM Linehan, MK Floeter, CC Chen, S Dixon, DR Kohler, EA Kruger, E Gubish, JM Pluda & E Reed: A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res 7, 1888-93 (2001)
125. Stadler WM, T Kuzel, C Shapiro, J Sosman, J Clark & NJ Vogelzang: Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma. J Clin Oncol 17, 2541-2545 (1999)
126. Herbst RS, AT Lee, HT Tran & JL Abbruzzese: Clinical studies of angiogenesis inhibitors: the University of Texas MD Anderson Center Trial of Human Endostatin. Curr Oncol Rep 3, 131-40 (2001)
127. Herbst RS, KR Hess, HT Tran, JE Tseng, NA Mullani, C Charnsangavej, T Madden, DW Davis, DJ McConkey, MS O'Reilly, LM Ellis, J Pluda, WK Hong & JL Abbruzzese: Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol. 20(18), 3792-3803 (2002)
128. Figg WD, P Arlen, J Gulley, P Fernandez, M Noone, K Fedenko, M Hamilton, C Parker, EA Kruger, J Pluda & WL Dahut: A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer. Semin Oncol 28, 62-6 (2001)
129. Tseng, JE, BS Glisson, FR Khuri, DM Shin, JN Myers, AK El-Naggar, JS Roach, LE Ginsberg, PF Thall, X Wang, S Teddy, KN Lawhorn, RE Zentgraf, GD Steinhaus, JM Pluda, JL Abbruzzese, WK Hong & RS Herbst: Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer 92, 2364-73 (2001)
130. Tennant TR, CW Schaeffer & WM Stadler: Angiogenesis inhibitors. Curr Oncol Rep 2, 11-16 (2000)
131. Eberhard A, S Kahlert, V Goede, B Hemmerlein, KH Plate & HG Augustin: Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 60, 1388-93 (2000)
132. Abdulrauf SI, K Edvardsen, KL Ho, XY Yang, JP Rock & ML Rosenblum: Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade astrocytoma. J Neurosurg 88, 513-20 (1998)
133. Kim KJ, B Li, J Winer, M Armanini, N Gillett, HS Phillips & N Ferrara: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362, 841-4 (1993)
134. Millauer B, LK Shawver, KH Plate, W Risau & A Ullrich: Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367, 576-9 (1994)
135. Saleh M, SA Stacker & AF Wilks: Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res 56, 393-401 (1996)
136. Vajkoczy P, MD Menger, R Goldbrunner, S Ge, TA Fong, B Vollmar, L Schilling, A Ullrich, KP Hirth, JC Tonn, P Schmeidek & SA Rempel: Targeting angiogenesis inhibits tumor infiltration and expression of the proinvasive protein SPARC. Int J Cancer 87, 261-8 (2000)
137. Kirsch M, J Strasser, R Allende, L Bello, J Zang & PM Black: Angiostatin suppresses malignant glioma growth in vivo. Cancer Res 58, 4654-9 (1998)
138. Sorensen DR, TA Read, T Porwol, BR Olsen, R Timol, T Sasaki, PO Iversen, HB Benestad, BK Sim & R Bjerkvig: Endostatin reduces vascularization, blood flow, and growth in a rat gliosarcoma. Neuro-oncol 4, 1-8 (2002)
139. Taki T, T Ohnishi, N Arita, S Hiraga, Y Saitoh, S Izumoto, K Mori & T Hayakawa: Anti-proliferative effects of TNP-470 on human malignant glioma in vivo: potent inhibition of tumor angiogenesis. J Neurooncol 19, 251-8 (1994)
140. Takano S, S Gately, H Engelhard, AM Tsanaclis & S Brem: Suramin inhibits glioma cell proliferation in vitro and in the brain. J Neurooncol 21, 189-201 (1994)
141. Brem S: Angiogenesis and Cancer Control: From Concept to Therapeutic Trial. Cancer Control 6, 436-458 (1999)
142. Dove A: Cell-based therapies g Joki T, M Machluf, A Atala, J Zhu, NT Seyfried, IF Dunn, T Abe, RS Carroll & PM Black: Continuous release of endostatin from microencapsulated engineered cells for tumor therapy. Nature Biotechnology 19, 35-9 (2001)
143. Read T, DR Sorensen, R Mahesparan, PO Enger, R Timpl, BR Olsen, MH Hjelstuen, O Haraldseth & R Bjerkvig: Local endostatin treatment of gliomas administered by microencapsulated producer cells. Nature Biotechnology 19, 29-34 (2001)
144. Soon-Shiong P, E Feldman, R Nelson, R Heintz, Q Yao, Z Yao, T Zheng, N Merideth, G. Skjak-Braek, T Espevik et al: Long-term reversal of diabetes by the injection of immunoprotected islets. Proc Natl Acad Sci U S A 90, 5843-5847 (1993)
145. Susick R, N Moss, H Kubota, E Lecluyse, G Hamilton, T Luntz, J Ludlow, J Fair, D Gerber, K Bergstrand, J White, A Bruce, O Drury, S Gupta & LM Reid: Hepatic progenitors and strategies for liver cell therapies. Ann N Y Acad Sci 944, 398-419 (2001)
146. Chang TM: Artificial cells with emphasis on cell encapsulation of genetically engineered cells. Artif Organs 22, 958-65 (1998)
147. Hasse C, A Zielke, G Klock, A Schlosser, U Zimmermann & M Rothmund: Isotransplantation of microencapsulated parathyroid tissue in rats. Exp Clin Endocrinol Diabetes 105, 53-6 (1997)
148. al-Hendy A, G Hortelano, GS Tannenbaum & PL Chang: Correction of the growth defect in dwarf mice with nonautologous microencapsulated myoblasts - an alternate approach to somatic gene therapy. Human Gene Therapy 6, 165-75 (1995)
149. Stockley TL, KE Robinson, K Delaney, FA Ofosu & P Chang: Delivery of recombinant product from subcutaneous implants of encapsulated recombinant cells in canines. J Lab Clin Med 135, 484-92 (2000)
150. Joseph JM, MB Goddard, J Mills, V Padrun, A Zurn, B Zielinski, J Favre, JP Gardaz, F Mosimann, & J Sagen: Transplantation of encapsulated bovine chromaffin cells in the sheep subarachnoid space: a preclinical study for the treatment of cancer pain. Cell Transplant 3, 355-64 (1994)
151. Hortelano G, A Al-Hendy, FA Ofosu & PL Chang: Delivery of human factor IX in mice by encapsulated recombinant myoblasts: a novel approach towards allogeneic gene therapy of hemophilia B. Blood 87, 5095-103 (1996)
152. Ross CJ, L Bastedo, SA Maier, MS Sands & PL Chang: Treatment of a lysosomal storage disease, mucopolysaccharidosis VII, with microencapsulated recombinant cells. Hum Gene Ther 11, 2117-2127 (2000)
153. Visted T, R Bjerkvig & PO Enger: Cell encapsulation technology as a therapeutic strategy for CNS malignancies. Neuro-Oncol 3, 201-210 (2000)
154. Read TA, F Thorsen & R Bjerkvig. Localised delivery of therapeutic agents to CNS malignancies: old and new approaches. Curr Pharm Biotechnol 3, 257-273 (2002)
155. Read TA, M Farhadi, R Bjerkvig, BR Olsen, AM Rokstad, PC Huszthy & P Vajkoczy: Intravital microscopy reveals novel antivascular and antitumor effects of endostatin delivered locally by alginate-encapsulated cells. Cancer Res 61, 6830-6837 (2001)
156. Thorsen F, TA Read, M Lund-Johansen, BB Tysnes & R Bjerkvig: Alginate encapsulated producer cells. A potential new approach for the treatment of malignant brain tumors. Cell Transplant 9, 773-783 (2000)
157. Nowell PC: The clonal evolution of tumor cell populations. Science 194, 23-8 (1976)
158. Scott HS & R Chrast: Global transcript expression profiling by Serial Analysis of Gene Expression (SAGE). Genet Eng (N Y) 23, 201-219 (2001)
159. Mariani L, WS McDonough, DB Hoelzinger, C Beaudry, E Kaczmarek, SW Coons, A Giese, M Moghaddam, RW Seiler & ME Berens: Identification and validation of P311 as a glioblastoma invasion gene using laser capture microdissection. Cancer Res 61, 4190-4196 (2001)